The future of tumor vaccines in the post‐COVID‐19 era—Current challenges
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-12-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.521 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849246031847358464 |
|---|---|
| author | Panagiotis F. Christopoulos |
| author_facet | Panagiotis F. Christopoulos |
| author_sort | Panagiotis F. Christopoulos |
| collection | DOAJ |
| format | Article |
| id | doaj-art-cd4fe03427214a60b37c579fe3d0d1c4 |
| institution | Kabale University |
| issn | 2050-4527 |
| language | English |
| publishDate | 2021-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj-art-cd4fe03427214a60b37c579fe3d0d1c42025-08-20T03:58:37ZengWileyImmunity, Inflammation and Disease2050-45272021-12-01941795179710.1002/iid3.521The future of tumor vaccines in the post‐COVID‐19 era—Current challengesPanagiotis F. Christopoulos0Department of Pathology, Section of Research Oslo University Hospital Rikshospitalet and University of Oslo Oslo Norwayhttps://doi.org/10.1002/iid3.521cancer vaccinesCOVID‐19immunotherapySARS‐CoV‐2 |
| spellingShingle | Panagiotis F. Christopoulos The future of tumor vaccines in the post‐COVID‐19 era—Current challenges Immunity, Inflammation and Disease cancer vaccines COVID‐19 immunotherapy SARS‐CoV‐2 |
| title | The future of tumor vaccines in the post‐COVID‐19 era—Current challenges |
| title_full | The future of tumor vaccines in the post‐COVID‐19 era—Current challenges |
| title_fullStr | The future of tumor vaccines in the post‐COVID‐19 era—Current challenges |
| title_full_unstemmed | The future of tumor vaccines in the post‐COVID‐19 era—Current challenges |
| title_short | The future of tumor vaccines in the post‐COVID‐19 era—Current challenges |
| title_sort | future of tumor vaccines in the post covid 19 era current challenges |
| topic | cancer vaccines COVID‐19 immunotherapy SARS‐CoV‐2 |
| url | https://doi.org/10.1002/iid3.521 |
| work_keys_str_mv | AT panagiotisfchristopoulos thefutureoftumorvaccinesinthepostcovid19eracurrentchallenges AT panagiotisfchristopoulos futureoftumorvaccinesinthepostcovid19eracurrentchallenges |